Enhanced RegIV Expression Predicts the Intrinsic 5-Fluorouracil (5-FU) Resistance in Advanced Gastric Cancer
- 342 Downloads
RegIV, a member of the Regenerating (REG) gene family, may be a marker for the prediction of resistance to 5-fluorouracil (5-FU)-based chemotherapy. However, the relationship between the intrinsic drug resistance of gastric cancer (GC) cells to 5-FU used alone (single FU) or in multidrug therapeutic regimens (5-FU combinations) and RegIV expression has not been investigated.
The patient cohort comprised 45 patients with primary GC. The chemoresistance of GC cells to therapeutic regimens consisting of single 5-FU or FU combinations was investigated using the ATP-tumor chemosensitivity assay. The level of RegIV mRNA transcripts was determined by real-time reverse transcriptase-PCR. RegIV expression was evaluated as a novel predictive biomarker for the intrinsic drug resistance of primary GC cells to single 5-FU or 5-FU combinations.
Upregulation of RegIV mRNA transcripts was observed in 36 of the 45 tumor specimens and was positively correlated with the invasive depth of the tumor cells (p = 0.000), the clinical stages (p = 0.000) and the in vitro intrinsic drug resistance of primary GC cells to 5-FU (p = 0.000) or 5-FU combinations.
RegIV mRNA transcript level was strongly associated with the intrinsic resistance of GC cells to single 5-FU or 5-FU combinations, suggesting that RegIV may play an important role in the intrinsic resistance of GC cells to 5-FU and that targeted therapy against the RegIV gene could be applied to overcome 5-FU resistance in the treatment of GC.
KeywordsGastric cancer Regenerating islet-derived family, member 4 (RegIV) 5-Fluorouracil ATP-tumor chemosensitivity assay Real-time reverse transcriptase-PCR
This research was partly supported by a grant from the Science and Technology General Project of Zhejiang Province (No. 2009C33143) and a grant from the Science and Technology Plan Projects of Zhejiang Provincial Medicine and Health (2009B029).
Conflict of interest
- 1.Treatment Architecture China: Gastric Cancer. KantarHealth and Draco Healthcare Consulting, LLC; 2009.Google Scholar
- 2.MattsonJack. CancerMPact. The Mattson Jack Group, Inc.; St. Louis, MO. 2009.Google Scholar
- 39.Bishnupuri KS, Luo Q, Sainathan SK, et al. Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. Gastroenterology. 2010;138(2):616–626 (626.e1-2).Google Scholar
- 42.Nakamura R, Saikawa Y, Wada N, et al. Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination. Gan Kagaku Ryoho. 2007;34:1827–1831.Google Scholar